Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Merck to buy EyeBio in $3 billion ophthalmology deal

EditorIsmeta Mujdragic
Published 05/29/2024, 02:27 PM
MRK
-

RAHWAY, N.J. - Merck & Co., Inc. (NYSE:MRK), a global healthcare leader, has announced the acquisition of EyeBio, a private biotech company specializing in ophthalmology, in a deal that could be worth up to $3 billion. The transaction includes an upfront cash payment of $1.3 billion with the potential for an additional $1.7 billion tied to future milestones.

The acquisition is poised to significantly enhance Merck's footprint in the ophthalmology sector, adding EyeBio's novel late-phase candidate Restoret™ for diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD) to its pipeline. Restoret™ is expected to enter a pivotal study for DME in the second half of 2024, following promising results from earlier clinical trials.

EyeBio's expertise in developing therapies for retinal diseases will be integrated into Merck's operations. The EyeBio leadership team, including founders Dr. David Guyer and Dr. Tony Adamis, will continue their work under Merck to advance the clinical development of Restoret™ and other programs.

The transaction, approved by EyeBio's Board of Directors, is subject to customary closing conditions, including the Hart-Scott-Rodino Antitrust Improvements Act. The deal is expected to close in the third quarter of 2024 and will be accounted for as an asset acquisition.

Merck anticipates recording a charge of approximately $1.3 billion, or $0.50 per share, which will be reflected in non-GAAP results for the quarter in which the transaction is finalized.

Restoret™ is an investigational, potentially first-in-class tetravalent, tri-specific antibody that targets the Wnt signaling pathway. It is designed to restore and maintain the blood-retinal barrier, addressing a significant unmet medical need in patients with retinal vascular diseases characterized by leakage.

The acquisition aligns with Merck's science-led business development strategy to diversify its pipeline. It follows less than three years after EyeBio's inception in August 2021, with the company successfully raising $130 million to date.

The information for this article is based on a press release statement.

InvestingPro Insights

Merck & Co. (NYSE:MRK) has made a strategic move to expand its portfolio in the ophthalmology space with the acquisition of EyeBio. This decision comes at a time when Merck's financial health and market performance show positive signs. With a robust market capitalization of $319.36 billion and a revenue growth of 6.11% over the last twelve months as of Q1 2024, Merck is positioning itself for further growth in the healthcare sector.

Investors should note that Merck's Price / Book ratio stands at 7.91, indicating a premium valuation compared to the book value of its assets. Additionally, the company is trading near its 52-week high, with a price that is 94.75% of this peak. While the P/E ratio is at a high of 138.68, the adjusted P/E ratio for the last twelve months as of Q1 2024 is considerably lower at 24.98, reflecting a more normalized earnings valuation.

Among the InvestingPro Tips for Merck, two particularly stand out in the context of this acquisition. Firstly, Merck has raised its dividend for 13 consecutive years, demonstrating a commitment to returning value to shareholders. Secondly, analysts have revised their earnings upwards for the upcoming period, which could be a reflection of confidence in Merck's growth trajectory, potentially buoyed by strategic acquisitions like that of EyeBio.

For investors looking to delve deeper into Merck's performance and future prospects, InvestingPro offers additional insights. There are 12 more InvestingPro Tips available, which can provide a more comprehensive analysis of Merck's financial health and market position. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking these valuable insights.

Merck's next earnings date is set for July 30, 2024, which may provide further information on the impact of the EyeBio acquisition and the company's overall performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.